The clinical effect of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease - including a long-term follow-up study Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020
M ycobacterium abscessus pulmonary disease: individual patient data meta-analysisSource: Eur Respir J, 54 (1) 1801991; 10.1183/13993003.01991-2018 Year: 2019
Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016 Year: 2017
Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Source: Eur Respir J 2003; 21: 478-482 Year: 2003
Characteristics and outcomes of 197 patients newly diagnosed with pulmonary mycobacterium avium complex disease Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections Year: 2017
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Clinical analysis of pulmonary Mycobacterium kansasii disease Source: International Congress 2018 – Difficult-to-treat respiratory infections Year: 2018
Clinical characteristics and outcomes of patients with Mycobacterium avium complex lung disease positive for Aspergillus precipitating antibody Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009
Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012
Treatment of human disease due to Mycobacterium bovis: a systematic review Source: Eur Respir J 2016; 48: 1500-1503 Year: 2016
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Mycobacterium abscessus infection in lung transplant patients: review of our seriesSource: Annual Congress 2007 - Complications and success in lung transplantation Year: 2007
Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 58 (2) 1902269; 10.1183/13993003.02269-2019 Year: 2021